The use of inhaled corticosteroids in chronically ventilated preterm infants

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Pharmacology

Background:

• Bronchopulmonary dysplasia (BPD) is a primary cause of chronic mechanical ventilation in preterm infants.
• Inflammation significantly contributes to lung injury and BPD development.
• Systemic corticosteroids, while effective, carry substantial adverse effects in preterm neonates.

Purpose of the Study:

• To review the current evidence on the efficacy and safety of inhaled corticosteroids (ICS) for BPD in ventilator-dependent preterm infants.
• To highlight the challenges in assessing ICS use due to limited high-grade evidence.
• To underscore the need for robust clinical trials on ICS in this vulnerable population.

Main Methods:

• Literature review and synthesis of existing studies on inhaled corticosteroids (ICS) in preterm infants with BPD.
• Analysis of available data regarding the efficacy and safety profiles of ICS.
• Identification of evidence gaps and limitations in current research.

Main Results:

• A significant lack of high-quality evidence exists regarding the use of ICS in chronically ventilated preterm infants.
• The safety and efficacy of ICS for BPD management remain incompletely understood.
• Existing data are insufficient to establish definitive clinical recommendations for ICS use.

Conclusions:

• While ICS present a theoretically safer option than systemic corticosteroids for BPD, robust clinical evidence is lacking.
• Well-powered randomized controlled trials are crucial to evaluate the short- and long-term outcomes of ICS in preterm infants.
• Further research is imperative to guide the clinical application of ICS in managing ventilator-dependent preterm infants with BPD.